Novelix Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
For 15 years, its founders dreamed of starting a company to design new cancer drugs, but it wasn't until 2005 that they were able to lock up all the compounds they wanted. Novelix Pharmaceuticals now boasts a preclinical pipeline that's four candidates strong--all novel, proprietary, small molecules with innovative modes of action and favorable ADMET profiles.